Journal of the Korean Association of Oral and Maxillofacial Surgeons

The Korean Association of Oral and Maxillofacial Surgeons (대한구강악안면외과학회)
권호 표지

IDENTIFICATION OF RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-${\kappa}B$ LIGAND(RANKL) AND OSTEOPROTEGERIN(OPG) IN AMELOBLASTOMA

법랑모세포종에서 Receptor Activatorof Nuclear Factor-${\kappa}B$ Ligand(RANKL)와 Osteoprotegerin(OPG) 발현에 관한 연구

  • Ha, Woo-Hun (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University) ;
  • Hwang, Dae-Seok (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University) ;
  • Kim, Yong-Deok (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University) ;
  • Shin, Sang-Hun (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University) ;
  • Kim, Uk-Kyu (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University) ;
  • Kim, Jong-Ryoul (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University) ;
  • Chung, In-Kyo (Dept. of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University)
  • 하우헌 (부산대학교 치과대학 구강악안면외과학교실) ;
  • 황대석 (부산대학교 치과대학 구강악안면외과학교실) ;
  • 김용덕 (부산대학교 치과대학 구강악안면외과학교실) ;
  • 신상훈 (부산대학교 치과대학 구강악안면외과학교실) ;
  • 김욱규 (부산대학교 치과대학 구강악안면외과학교실) ;
  • 김종렬 (부산대학교 치과대학 구강악안면외과학교실) ;
  • 정인교 (부산대학교 치과대학 구강악안면외과학교실)
  • Published : 2007.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

The ameloblastoma is a common odontogenic tumor of the jaw bone and represents approximately 1% of tumor in the jaw. However, it might be able to infiltrate into the adjacent tissue, causing bony destruction and high recurrent rate. In this study, expression of RANKL and OPG in ameloblastoma in relation to age and gender of patient and recurrence, location of the lesion were examined through immunohistochemisry study. The RANKL and OPG antibody staining were used. The obtained result were as follow. 1. Positive immunoreactivity to RANKL/OPG in all specimens was found. 2. 1n recurrenc, location of ameloblastoma and age, gender of patients using immunohistochemical expression of RANKL. There was not significant difference. 3. 1n recurrence, location of ameloblastoma and age, gender of patients using immunohistochemical expression of OPG. There was not significant difference. In summary, it is suggested that activation of osteoclasts by RANKL is an important mechanism by which ameloblastomas cause bone destruction.

Keywords

References

  1. Barns L: Surgical pathology of the head and neck. New York, Marcel Dekker. 1986, 1332
  2. Neville, Damm, Allen, Bouquot: Oral and maxillofacial pathology. Philadelphia, W.B. Saunders Co. 2002, 611-9
  3. Tsuda E, Goto M, Michizuki S, Yano K, Kobayashi F, Morinaga T, Hisgashio K: Isolation of a novel cytokine from human fibroblast that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137-42 https://doi.org/10.1006/bbrc.1997.6603
  4. Wttrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Redini F: RANKL/RANK/OPG: new therapeutic targets in bone tumors and associated osteolysis. Bioch et Biophys Acta 2004;1704:49-57
  5. Rousselle AV, Heymann D: Osteoclastic acidication during bone resorption. Bone 2002;30:533-40 https://doi.org/10.1016/S8756-3282(02)00672-5
  6. Takahashi N, Akatsu T, Saaki T, Yamaguchi A, Moseley JM, Martin TJ, et al: Osteoclastic cells are involved in osteoclast formation. Endocrinology 1998;123:2600-2
  7. Jimi E, Nakamura I, Amano H, Taguchi Y, Tsurukai T, Tamura M, et al: Osteoclast function is activated by osteoclastic cells through a mechanism involving cell-to-cell contact. Endocrinology 1997;137:2187-90
  8. Lacey DL, Timms E, Tan HL, Kelly MJ, Dunstan CR, Burgess T, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76 https://doi.org/10.1016/S0092-8674(00)81569-X
  9. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuchi SI, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602?쳘
  10. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ: TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997-1001 https://doi.org/10.1084/jem.188.5.997
  11. O'Brien EA, Williams JH, Marshall MJ: Osteoprotegerin ligand regulates osteoclast adherence to the bone surface of mouse calvaria. Biochem Biophys Res Commun 2000;274:281-90 https://doi.org/10.1006/bbrc.2000.3129
  12. Wong BG, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-4 https://doi.org/10.1074/jbc.272.40.25190
  13. Nagai M, Kyakumoto S, Sato N: Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun 2000;269:532-6 https://doi.org/10.1006/bbrc.2000.2314
  14. Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin. a novel secreted protein involved in the regulation of bone densty. Cell 1997;89:309-19 https://doi.org/10.1016/S0092-8674(00)80209-3
  15. Guise TA, Mundy GR: Cancer and bone. Endocr. Rev. 1998;19:18- 54 https://doi.org/10.1210/er.19.1.18
  16. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russel GR, Van Camp B, Vanderkerken K: Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98:3534-40 https://doi.org/10.1182/blood.V98.13.3534
  17. Zhang Dai J, Qi Y, Lin D.L, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET: Osteoprotegerin inhibits prostate cancerinduced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44 https://doi.org/10.1172/JCI11685
  18. Hofbauer LC, Gori F, Rigg BL, Lacey LD, Dunstan DR, Spielsberg TC, et al: Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoid in human osteoblastic lineage cells: potential paracrine mechanism of glucocorticoid induced osteoporosis. Endocrinology 1999;140:4382-9 https://doi.org/10.1210/en.140.10.4382
  19. Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D: RANKL/OPG ratio in increased in severe osteolysis. Am J Pathol 2003;163:2021-31 https://doi.org/10.1016/S0002-9440(10)63560-2
  20. Wong BG, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-4 https://doi.org/10.1074/jbc.272.40.25190
  21. Lacey DL, Timms E, Tan HL, Kelly MJ, Dunstan CR, Burgess T, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76 https://doi.org/10.1016/S0092-8674(00)81569-X
  22. Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K, et al: Transforming growth factor-beta stimulates the production of osteoprotegerin/ osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 1998;273:27091-6 https://doi.org/10.1074/jbc.273.42.27091
  23. Kitazawa R, Kitazawa S, Maeda S: Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Boichem Biophys Acta 1999;1445:134-41 https://doi.org/10.1016/S0167-4781(99)00032-9
  24. Lee SK, Lorenzo JA: Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552-61 https://doi.org/10.1210/en.140.8.3552
  25. Good CR, O'Keefe RJ, Puzas JE, Schwarz EM, Rosier RN: Immunohistochemical study of RANKL in human osteolytic bone tumors. J Surg Oncol 2002;79:174-9 https://doi.org/10.1002/jso.10067
  26. Rani CSS, MacDougall M: Dental cells express factors that regulate bone resorption. Mol Cell Biol Res Comm 2000;3:145-52 https://doi.org/10.1006/mcbr.2000.0205
  27. Wise GE, Lumpkin SJ, Huang H, Zhang Q: Osteoprotegerin and osteoclst differentiation factor in tooth eruption. J Dent Res 2000;79:1937-42 https://doi.org/10.1177/00220345000790120301
  28. Hiroyuki K, Kiyoshi O: Expression of PTHrP, ODF/RANKL and OCIF/OPG in ameloblastoma. J Oral Pathol Med 2004;33:46-52 https://doi.org/10.1111/j.1600-0714.2004.00204.x
  29. Tay JYY, Bay BH, Yeo JF, Harris M, Meghji S, Dheen ST: Identification of RANKL in osteolytic lesions of the facial skeleton. J Dent Res 2004;83:349-53 https://doi.org/10.1177/154405910408300415
  30. Kawamoto S, Ejiri S, Hoshi K, Nahaoka E, Ozawa H: Immunolocalization of osteoclast differentiation factor in rat periodontium. Arch Oral Biol 2002;47:55-58 https://doi.org/10.1016/S0003-9969(01)00088-7
  31. Horowizt MC, Xi Y, Wilson K, Kacena MA: Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 2001;12:9-18 https://doi.org/10.1016/S1359-6101(00)00030-7
  32. Miyamoto T, Ohneda O, Arai F, Iwamoto K, Okada S, Takagi K, et al: Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001;98:2544-2554 https://doi.org/10.1182/blood.V98.8.2544
  33. Gardner DC: Controversies in the nomenclature, diagnosis and treatment of ameloblastoma. Controversies in Oral and maxillofacial Surgery. Philadelphia, W.B Saunders, 1994, 301
  34. Hartman Ks: Granular cell ameloblastoma. Oral Surg Oral Med Oral Pathol 1974;38:241 https://doi.org/10.1016/0030-4220(74)90063-2
  35. Khanna S, Khanna NN: Predicting recurrence in the mandibular and maxillary ameloblastoma. Ear Nose Throat J 1978;57:56
  36. Piattelli A, Fioroni M, Santinelli A, Rubini C: Expression of proliferating cell nuclear antigen in ameloblastoma and odontogenic cysts. Oral Oncology 1998;34:408-12 https://doi.org/10.1016/S1368-8375(98)00027-X